Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor

Journal of Immunology

Volumn 179, Issue 5, 2007, Pages 2766-2773

  Chen, Yingying ^a   Perussia, Bice ^a   Campbell, Kerry S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CYCLIC AMP; D PROSTANOID RECEPTOR; PROSTAGLANDIN D2; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN RECEPTOR; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ARTICLE; CALCIUM MOBILIZATION; CELL FUNCTION; CHEMOTAXIS; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RNA ANALYSIS; WESTERN BLOTTING; APOPTOSIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM;

APOPTOSIS; CELLS, CULTURED; CYCLIC AMP; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; PROSTAGLANDIN D2; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 38049163745     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.5.2766     Document Type: Article

References (63)

1. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7: 145-173.
2. Salazar-Mather, T. P., and K. L. Hokeness. 2006. Cytokine and chemokine networks: pathways to antiviral defense. Curr. Top. Microbiol. Immunol. 303: 29-46.
3. Daser, A., N. Meissner, U. Herz, and H. Renz. 1995. Role and modulation of T-cell cytokines in allergy. Curr. Opin. Immunol. 7: 762-770.
4. Baraniuk, J. N. 1997. Pathogenesis of allergic rhinitis. J. Allergy Clin. Immunol. 99: S763-S772.
5. Lucey, D. R., M. Clerici, and G. M. Shearer. 1996. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9: 532-562.
6. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178: 567-577.
7. Martin-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-γ for Th1 priming. Nat. Immunol. 5: 1260-1265.
8. Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and G. Trinchieri. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195: 327-333.
9. Jira, M., E. Antosova, V. Vondra, J. Strejcek, H. Mazakova, and J. Prazakova. 1988. Natural killer and interleukin-2 induced cytotoxicity in asthmatics. I. Effect of acute antigen-specific challenge. Allergy 43: 294-298.
10. Hall, T. J., R. Rycroft, and J. Brostoff. 1985. Decreased natural killer cell activity in atopic eczema. Immunology 56: 337-344.
11. Sakai, R., M. Aihara, M. Ishiwa, A. Negishi, S. Matsukura, K. Takahashi, H. Kimura, K. Kosaka, and Z. Ikezawa. 2003. Natural killer cell activity among patients with atopic dermatitis. Arerugi 52: 1074-1080.
12. Jensen, J. R., T. T. Sand, A. S. Jorgensen, and K. Thestrup-Pedersen. 1984. Modulation of natural killer cell activity in patients with atopic dermatitis. J. Invest. Dermatol. 82: 30-34.
13. Morris, M. A., and K. Ley. 2004. Trafficking of natural killer cells. Curr. Mol. Med. 4: 431-438.
14. Chong, A. S., I. A. Boussy, X. L. Jiang, M. Lamas, and L. H. Graf Jr. 1994. CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol. 157: 92-105.
15. Lin, S. J., L. Y. Chang, D. C. Yan, Y. J. Huang, T. J. Lin, and T. Y. Lin. 2003. Decreased intercellular adhesion molecule-1 (CD54) and L-selectin (CD62L) expression on peripheral blood natural killer cells in asthmatic children with acute exacerbation. Allergy 58: 67-71.
16. Mikus, L. D., L. A. Rosenthal, R. L. Sorkness, and R. F. Lemanske Jr. 2001. Reduced interferon-γ secretion by natural killer cells from rats susceptible to postviral chronic airway dysfunction. Am. J. Respir. Cell Mol. Biol. 24: 74-82.
17. Robinson, C., C. C. Hardy, and S. T. Holgate. 1985. Pulmonary synthesis, release, and metabolism of prostaglandins. J. Allergy Clin. Immunol. 76: 265-271.
18. 2 into human airways during acute antigen challenge. N. Engl. J. Med. 315: 800-804.
19. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193: 255-261.
20. Balter, M. S., W. L. Eschenbacher, and M. Peters-Golden. 1988. Arachidonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am. Rev. Respir. Dis. 138: 1134-1142.
21. Pearce, F. L., K. C. Flint, K. B. Leung, B. N. Hudspith, K. Seager, M. D. Hammond, J. Brostoff, D. Geraint-James, and N. M. Johnson. 1987. Some studies on human pulmonary mast cells obtained by bronchoalveolar lavage and by enzymic dissociation of whole lung tissue. Int. Arch. Allergy Appl. Immunol. 82: 507-512.
22. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98: 1942-1948.
23. 2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J. Immunol. 170: 4943-4952.
24. Boie, Y., N. Sawyer, D. M. Slipetz, K. M. Metters, and M. Abramovitz. 1995. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270: 18910-18916.
25. 2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur. J. Immunol. 33: 889-898.
26. 2 on helper T cell functions. Biochem. Biophys. Res. Commun. 316: 1009-1014.
27. 2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptorlike molecule expressed on Th2 cells. J. Immunol. 175: 6531-6536.
28. 2. Immunol. Lett. 7: 141-144.
29. Bankhurst, A. D. 1982. The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol. 7: 85-91.
30. Loza, M. J., L. Zamai, L. Azzoni, E. Rosati, and B. Perussia. 2002. Expression of type 1 (interferon γ) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 99: 1273-1281.
31. Trotta, R., K. A. Puorro, M. Paroli, L. Azzoni, B. Abebe, L. C. Eisenlohr, and B. Perussia. 1998. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J. Immunol. 161: 6648-6656.
32. Nagata, K., K. Tanaka, K. Ogawa, K. Kemmotsu, T. Imai, O. Yoshie, H. Abe, K. Tada, M. Nakamura, K. Sugamura, and S. Takano. 1999. Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol. 162: 1278-1286.
33. 2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J. Immunol. 171: 3936-3940.
34. Berahovich, R. D., N. L. Lai, Z. Wei, L. L. Lanier, and T. J. Schall. 2006. Evidence for NK cell subsets based on chemokine receptor expression. J. Immunol. 177: 7833-7840.
35. - natural killer cells is selectively responsible for both cell proliferation and interferon-γ production upon interaction with dendritic cells. Eur. J. Immunol. 34: 1715-1722.
36. 2, and peroxisome proliferator activated receptor-γ agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 105: 23-34.
37. 2 and its metabolites in leukocyte function. J. Leukocyte Biol. 81: 372-382.
38. Gjertsen, B. T., G. Mellgren, A. Otten, E. Maronde, H. G. Genieser, B. Jastorff, O. K. Vintermyr, G. S. McKnight, and S. O. Doskeland. 1995. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture: basal cAMP-kinase activity modulates interleukin-1β action. J. Biol. Chem. 270: 20599-20607.
39. 2 in freshly isolated nonchromaffin cells from bovine adrenal medulla. Biochim. Biophys. Acta 1176: 148-154.
40. 2+ in FcγR(CD16)-induced transcription and expression of lymphokine genes. J. Exp. Med. 169: 549-567.
41. Orange, J. S., K. E. Harris, M. M. Andzelm, M. M. Valter, R. S. Geha, and J. L. Strominger. 2003. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc. Natl. Acad. Sci. USA 100: 14151-14156.
42. Bryceson, Y. T., M. E. March, D. F. Barber, H. G. Ljunggren, and E. O. Long. 2005. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202: 1001-1012.
43. Ullberg, M., M. Jondal, F. Lanefelt, and B. B. Fredholm. 1983. Inhibition of human NK cell cytotoxicity by induction of cyclic AMP depends on impaired target cell recognition. Scand. J. Immunol. 17: 365-373.
44. MacFarlane IV, A. W., and K. S. Campbell. 2006. Signal transduction in natural killer cells. Curr. Top. Microbiol. Immunol. 298: 23-57.
45. Campbell, K. S., and M. Colonna. 2001. Human natural killer cell receptors and signal transduction. Int. Rev. Immunol. 20: 333-370.
46. - large granular lymphocyte functions by agonist and antagonists of protein kinase C: effects on NK and lymphokine-activated killer activity and production of IFN-γ. J. Immunol. 143: 366-371.
47. 2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology 111: 298-305.
48. Zhang, X., M. C. Rodriguez-Galan, J. J. Subleski, J. R. Ortaldo, D. L. Hodge, J. M. Wang, O. Shimozato, D. A. Reynolds, and H. A. Young. 2004. Peroxisome proliferator-activated receptor-γ and its ligands attenuate biologic functions of human natural killer cells. Blood 104: 3276-3284.
49. Lang, N. P., J. R. Ortaldo, G. D. Bonnard, and R. B. Herberman. 1982. Interferon and prostaglandins: effects on human natural and lectin-induced cytotoxicity. J. Natl. Cancer Inst. 69: 339-343.
50. Vitale, M., M. Della Chiesa, S. Carlomagno, D. Pende, M. Arico, L. Moretta, and A. Moretta. 2005. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 106: 566-571.
51. - human natural killer cells. Blood 102: 1569-1577.
52. Goto, T., R. B. Herberman, A. Maluish, and D. M. Strong. 1983. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J. Immunol. 130: 1350-1355.
53. Leung, K. H., and H. S. Koren. 1984. Regulation of human natural killing. III. Mechanism for interferon induction of loss of susceptibility to suppression by cyclic AMP elevating agents. J. Immunol. 132: 1445-1450.
54. Roder, J. C., and M. Klein. 1979. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J. Immunol. 123: 2785-2790.
55. Yang, B. C., H. K. Lin, W. S. Hor, J. Y. Hwang, Y. P. Lin, M. Y. Liu, and Y. J. Wang. 2003. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway. J. Immunol. 171: 3947-3954.
56. Tan, K. S., A. G. Nackley, K. Satterfield, W. Maixner, L. Diatchenko, and P. M. Flood. 2007. β2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-κB-independent mechanisms. Cell. Signal. 19: 251-260.
57. Aronoff, D. M., C. Canetti, C. H. Serezani, M. Luo, and M. Peters-Golden. 2005. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J. Immunol. 174: 595-599.
58. Windebank, K. P., R. T. Abraham, G. Powis, R. A. Olsen, T. J. Barna, and P. J. Leibson. 1988. Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. J. Immunol. 141: 3951-3957.
59. 2+ current in canine colonic myocytes by cyclic nucleotide-dependent mechanisms. Am. J. Physiol. 271: C794-C803.
60. Ting, A. T., K. J. Einspahr, R. T. Abraham, and P. J. Leibson. 1991. Fcγ receptor signal transduction in natural killer cells: coupling to phospholipase C via a G protein-independent, but tyrosine kinase-dependent pathway. J. Immunol. 147: 3122-3127.
61. 2 is released during acute allergic bronchospasm in man. Trans. Assoc. Am. Physicians 98: 275-280.
62. 2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am. Rev. Respir. Dis. 142: 126-132.
63. Matsuoka, T., M. Hirata, H. Tanaka, Y. Takahashi, T. Murata, K. Kabashima, Y. Sugimoto, T. Kobayashi, F. Ushikubi, Y. Aze, et al. 2000. Prostaglandin D2 as a mediator of allergic asthma. Science 287: 2013-2017.